Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 6, 2013, Pages 1112-1122

  Chiu, Yi Lin ^a   Rubin, David T ^b   Vermeire, Severine ^c   Louis, Edouard ^d   Robinson, Anne M ^a   Lomax, Kathleen G ^a   Pollack, Paul F ^a   Paulson, Susan K ^a  

^a ABBVIE INC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anti TNF agents; Exposure response relationship; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; MERCAPTOPURINE; METHOTREXATE; PLACEBO;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GENDER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; CROHN DISEASE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84879197786     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182813242     Document Type: Article

References (32)

1. Etchevers MJ, Ordas I, Ricart E. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. Drugs. 2010;70:109-120.
2. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148-1157.
3. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut. 1997; 40:443-448.
4. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
6. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357: 239-250.
7. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106:685-698.
8. Afif W, Loftus Jr EV, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105: 1133-1139.
9. Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774-781.
10. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2008;103:944-948.
11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
12. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
13. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
14. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
15. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
16. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
17. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
18. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
19. Paulson SK, Noertersheuser PA, Pollack P, et al. Parmacokinetis of adalimumab from CLASSIC, a randomized Phase 3 trial for the induction of clinical remission in patients with Crohn's disease. Gastroenterology. 2005; 128(suppl 2):A-585.
20. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25: 1700-1721.
21. Salford Systems. CART for Window's User's Guide, Version 6.0. San Diego, CA: Salford Systems; 2007, pp. 38-137.
22. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39: 561-577.
23. Colombel JF, Feagan BG, Sandborn WJ, et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18: 349-358.
24. Ordas I, Mould DR, Feagan BG, et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91:635-646.
25. Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48:297-308.
26. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459.
27. Rubin DT. Strategies for maximizing and extending response to biologic therapy. Gastroenterol Hepatol. 2009;4(suppl 12):6-8.
28. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
29. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34(Suppl 1):12-18.
30. HUMIRA [Package Insert]. North Chicago, IL: AbbVie Inc.; 2012.
31. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11:81-88.
32. Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63-70; e65; quiz e31.